Published: 30 April 2021
Author(s): Stefania Paolillo, Simona Dell'Aversana, Immacolata Esposito, Alessandra Poccia, Pasquale Perrone Filardi
Issue: June 2021
Section: Review article

β-blockers represent a mainstay in the pharmacological approach to patients affected by heart failure with reduced ejection fraction (HFrEF). However, underuse of this class of drugs is still reported, especially in the presence of cardiovascular and non-cardiovascular comorbidities, even if they are not contraindications for prescription of a β-blocker. The prognostic benefit of β-blockers is relevant in the presence of comorbidities, and achievement of the maximum tolerated dose is an important goal to increase their favorable prognostic role.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.